China Resources Pharmaceutical Research Institute (Shenzhen) Co. Ltd. has prepared and tested Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Cytosinlab Therapeutics Co. Ltd. has synthesized G/T mismatch-specific thymine DNA glycosylase (TDG) inhibitors reported to be useful for the treatment of cancer.
Current treatments for Alzheimer’s disease have limited effects. While they can slow cognitive decline or alleviate symptoms, they do not reverse this complex neurodegenerative condition caused by multiple factors. Researchers from the Gladstone Institutes and the University of California, San Francisco (UCSF) have screened FDA-approved drugs in search of agents that could potentially modify the disease.
Thirty-six biotechnology, pharmaceutical and medical device companies sought a capital raise on the Hong Kong Stock Exchange in the first half (H1) of 2025, a review by BioWorld found. Of those, 34 companies were from mainland China.
Thirty-six biotechnology, pharmaceutical and medical device companies sought a capital raise on the Hong Kong Stock Exchange in the first half (H1) of 2025, a review by BioWorld found. Of those, 34 companies were from mainland China.
Dispatch Biotherapeutics Inc. is taking aim at solid tumors with a new viral vector/antigen technology backed by major industry names such as Arch Venture Partners and Bristol Myers Squibb Co. With offices in Philadelphia and San Francisco, Dispatch has raised $216 million since its founding in 2022. The firm’s platform delivers a cell-specific viral vector carrying a novel, universal antigen called Flare that tags solid, epithelial-derived tumor cells. Acting as a beacon, the Flare antigen directs the immune system to find and clear the cancer cells without harming healthy tissue.
Jacobio Pharmaceuticals Co. Ltd. has reported new fused tetracyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors potentially useful for the treatment of cancer.
Crossbow Therapeutics Inc. has nominated its second development candidate, CBX-663, a T-cell engager for the treatment of a broad range of solid tumors and hematologic malignancies.
The combination of interleukin-2 (IL-2) agonism with programmed cell death protein 1 (PD-1) checkpoint inhibition has previously demonstrated synergistic efficacy in promoting antitumor T-cell responses. However, the incompatible dose levels and dosing schedules of the two therapeutic mechanisms have made their integration within a single molecule challenging.
Akari Therapeutics plc announced that it is continuing key research on its antibody-drug conjugate (ADC) payload PH1 to further demonstrate its ability to target cancers fueled by oncogenic drivers. PH1 is a spliceosome modulator designed to disrupt RNA splicing within cells. It binds spliceosome proteins SF3B1 and PH5α and targets normal splicing of pre-mRNA. PH1 is a spliceosome modulator designed to disrupt RNA splicing within cells. It binds spliceosome proteins SF3B1 and PH5α and targets normal splicing of pre-mRNA.
RSS
